Fractyl Health (GUTS) to Release Quarterly Earnings on Tuesday

Fractyl Health (NASDAQ:GUTS) is expected to post its Q2 2026 results after the market closes on Tuesday, August 11th. Analysts expect the company to post earnings of ($0.15) per share for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, August 10, 2026 at 4:30 PM ET.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.23. On average, analysts expect Fractyl Health to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Fractyl Health Trading Up 3.2%

GUTS traded up $0.02 during trading on Tuesday, hitting $0.70. 343,912 shares of the company’s stock were exchanged, compared to its average volume of 3,443,564. Fractyl Health has a 1 year low of $0.38 and a 1 year high of $2.44. The stock has a 50 day moving average price of $0.78 and a 200 day moving average price of $0.74. The firm has a market cap of $110.90 million, a P/E ratio of -0.54 and a beta of 2.32. The company has a current ratio of 4.28, a quick ratio of 4.28 and a debt-to-equity ratio of 1.41.

Insider Buying and Selling at Fractyl Health

In other news, Director William Bradley purchased 68,493 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The shares were purchased at an average price of $0.73 per share, with a total value of $49,999.89. Following the purchase, the director directly owned 84,622 shares of the company’s stock, valued at approximately $61,774.06. This represents a 424.66% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ian Sheffield acquired 35,000 shares of the business’s stock in a transaction on Wednesday, June 10th. The stock was purchased at an average price of $0.73 per share, for a total transaction of $25,550.00. Following the acquisition, the director directly owned 35,000 shares in the company, valued at $25,550. This represents a ? increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 171,493 shares of company stock worth $127,150 in the last ninety days. 8.52% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of GUTS. Jane Street Group LLC acquired a new stake in Fractyl Health during the 2nd quarter valued at approximately $31,000. Scientech Research LLC purchased a new position in shares of Fractyl Health during the 3rd quarter valued at approximately $49,000. Prelude Capital Management LLC acquired a new stake in shares of Fractyl Health during the third quarter worth approximately $55,000. Jump Financial LLC bought a new stake in shares of Fractyl Health in the fourth quarter worth $57,000. Finally, Centiva Capital LP bought a new stake in shares of Fractyl Health in the third quarter worth $78,000.

Analyst Ratings Changes

Several equities analysts recently weighed in on GUTS shares. Weiss Ratings upgraded shares of Fractyl Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. Craig Hallum initiated coverage on Fractyl Health in a research report on Wednesday, July 1st. They issued a “buy” rating and a $4.00 price objective on the stock. Wall Street Zen upgraded Fractyl Health from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a report on Thursday, June 4th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.12.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.